Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?

Telehealth darling Hims Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable.

Benzinga

Why Hims & Hers Stock Could Be a Multi-Bagger in the Making

Hims & Hers stock keeps giving investors more reasons to buy, and has all the right factors to turn it into a potential multi-bagger investment.

MarketBeat

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Benzinga

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

Barchart

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

International Business Times UK

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Benzinga

Hims & Hers Stock: Buy the Dip or Wait It Out?

Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.

MarketBeat

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

MarketBeat

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Kiplinger

Hims & Hers Stock Chart Points to Strong Bullish Continuation

Hims & Hers Health, Inc. stock price action shows strongly bullish signs in May and could be ready to hit new highs before the 2nd half starts.

MarketBeat

Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

MarketBeat

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

MarketBeat

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

MarketBeat Week in Review – 03/03 - 03/07

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

Barchart

Hims & Hers Health Sparks Investors Interest with Unusual Options Trading

Hims and Hers Health produced sterling results on Feb. 24, spurring huge interest in HIMS call options trading. Barchart reported an unusual volume today in HIMS call options that expire on March 14.

MarketBeat

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

Barchart

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

MarketBeat

MarketBeat Week in Review – 02/17 - 02/21

Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news

MarketBeat

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

1 … 3 4 5 6

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.